-
公开(公告)号:EP3978483B1
公开(公告)日:2024-09-25
申请号:EP21190677.1
申请日:2017-04-05
IPC分类号: C07D261/04 , A61K31/42 , A61P33/00
CPC分类号: C07D261/04 , A61K31/42 , A61P33/00 , Y02A50/30
-
公开(公告)号:EP4417218A2
公开(公告)日:2024-08-21
申请号:EP24178574.0
申请日:2017-04-20
发明人: BERGMANN, Andreas
IPC分类号: A61K39/395
CPC分类号: G01N33/574 , G01N33/6893 , G01N2333/94820130101 , G01N2800/2620130101 , G01N2800/32520130101 , G01N2800/34720130101 , C07K16/40 , A61K2039/50520130101 , A61K2039/54520130101 , C07K2317/7320130101 , C07K2317/7620130101 , C07K2317/9020130101 , A61P1/16 , A61P13/12 , A61P17/02 , A61P25/00 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P33/00 , A61P33/06 , A61P35/00 , A61P9/00 , A61P9/02 , A61P9/04 , A61P9/10 , Y02A50/30
摘要: The present invention is directed to methods for determining active DPP3 in a bodily fluid sample, an assay or kit for determining active DPP3 in a bodily fluid sample, a method for diagnosing a disease or condition in a subject accompanied by or related to necrotic processes and methods of treating or preventing said disease.
-
公开(公告)号:EP3709998B1
公开(公告)日:2024-08-14
申请号:EP18879326.9
申请日:2018-11-14
-
公开(公告)号:EP3107912B1
公开(公告)日:2024-07-10
申请号:EP15702765.7
申请日:2015-02-05
IPC分类号: C07D471/04 , C07D498/04 , C07D473/40 , C07D213/74 , C07D213/73 , C07D487/04 , A61P33/00 , A01N43/90
CPC分类号: A01N43/90 , C07D213/73 , C07D213/74 , C07D473/40 , C07D498/04 , C07D471/04 , C07D487/04 , A61P33/00
-
公开(公告)号:EP4389116A1
公开(公告)日:2024-06-26
申请号:EP23151010.8
申请日:2023-01-10
申请人: Dechra Ltd
发明人: MICHIELS, Henricus Fransiscus Catharina , FOLMER, Brigitte Johanna Bernita , LEJEUNE, Stephan Jacob
CPC分类号: A61K47/10 , A61K9/0056 , A61K9/10 , A61K9/146 , A61K31/4184 , A61P33/00 , A61P33/10
摘要: The present invention relates to a pharmaceutical aqueous suspension comprising: at most 35 wt.% of flubendazole, based on the weight of the pharmaceutical aqueous suspension, as solid particles having a particle size distribution in which D50 ≤ 0.45 micrometer and ≥ 90 % of particles are ≤ 1.0 micrometer; a non-ionic triblock copolymer surfactant comprising a central polypropylene oxide)-block having at least 30 propylene oxide (PO) units, flanked by two poly(ethylene oxide)-blocks, each having at a certain number of ethylene oxide (EO) units, wherein the ratio of number of PO units to total number of EO units is at least 0.2, one or more preservatives, and water. In addition, the present invention relates to a medicated water and a concentrated water comprising water and the pharmaceutical aqueous suspension as well as to a process of preparing a pharmaceutical aqueous suspension and to a use of the pharmaceutical aqueous suspension for the treatment of internal parasites in mammals, such as poultry and pigs.
-
-
公开(公告)号:EP3269737B1
公开(公告)日:2024-06-19
申请号:EP17174600.1
申请日:2009-01-14
IPC分类号: C07K16/28 , A61K39/395 , C12N15/13 , A61P35/00 , A61K51/10 , A61K39/00 , A61K38/05 , A61K45/06 , A61K31/537 , C07K16/30 , G01N33/574 , A61K47/68 , A61P1/04 , A61P1/16 , A61P1/18 , A61P3/10 , A61P5/14 , A61P7/00 , A61P7/04 , A61P7/06
CPC分类号: A61K51/1027 , A61K2039/50520130101 , C07K2317/9220130101 , C07K2317/3420130101 , A61K47/6803 , A61K47/6811 , A61K47/6849 , A61K47/6867 , C07K16/2803 , A61K38/05 , A61K31/537 , A61P11/00 , A61P13/12 , A61P15/08 , A61P17/00 , A61P19/02 , A61P21/00 , A61P25/00 , A61P27/02 , A61P29/00 , A61P31/04 , A61P33/00 , A61P35/00 , A61P35/02 , A61P37/06 , A61P43/00 , A61P5/14 , A61P7/00 , A61P9/00 , Y02A50/30
-
公开(公告)号:EP3125952B1
公开(公告)日:2024-06-19
申请号:EP15773297.5
申请日:2015-03-26
IPC分类号: A61K8/20 , A61Q11/00 , A61L2/16 , A61K33/18 , A01N59/12 , A61K45/06 , A61K31/045 , A61K31/19 , A61K31/327 , A61K33/40 , C11D3/48 , A23B4/20 , A23B7/154 , A23L3/3463 , A61P31/10 , A23L3/3481 , A61Q15/00 , C02F1/50 , A23L3/3508
CPC分类号: A61K33/18 , A61K45/06 , A61K31/045 , A61K31/19 , A61K31/327 , A61K31/4245 , A61K33/40 , C11D3/485 , A23B4/20 , A23B4/24 , A23B7/157 , A23L3/349 , A23L3/3508 , A23L3/358 , C02F1/66 , C02F2103/4220130101 , A23L3/3463 , A23L3/3481 , A23B7/154 , A61Q11/00 , A61Q15/00 , A61K8/20 , A01N59/12 , C02F1/50 , C02F1/722 , C02F1/766 , C02F2303/0420130101 , A61P31/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P33/00 , Y02A50/30
-
公开(公告)号:EP4374157A2
公开(公告)日:2024-05-29
申请号:EP22846873.2
申请日:2022-07-22
CPC分类号: C07D401/12 , C07H19/167 , C07D241/24 , A61P33/00 , C09B11/22
-
公开(公告)号:EP4331604A3
公开(公告)日:2024-05-29
申请号:EP23214687.8
申请日:2009-12-08
发明人: IRVING, Bryan , CHEUNG, Jeanne , CHIU, Henry , LEHAR, Sophie , MAECKER, Heather , MARIATHASAN, Sanjeev , WU, Yan
IPC分类号: C07K16/28 , A61P35/00 , A61K39/395
CPC分类号: A61K39/3955 , A61K2039/50520130101 , A61K2039/50720130101 , C07K16/1063 , C07K16/22 , C07K2317/5620130101 , C07K2317/56520130101 , C07K2317/56720130101 , C07K2317/7120130101 , C07K2317/9220130101 , C07K2317/7320130101 , C07K2317/7420130101 , C07K2317/7620130101 , C07K16/2827 , A61P31/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P33/00 , A61P33/02 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/04 , A61P43/00 , Y02A50/30 , A61K39/00
摘要: The present application relates to anti-PD-Ll antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
-
-
-
-
-
-
-
-
-